Hyqvia Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Hyqvia market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to factors such as the rise in global healthcare expenditure, increased awareness of autoimmune disorders, the growing use of combination therapies, higher investment in biotechnology, and the increasing prevalence of autoimmune diseases.

Market growth during the forecast period can be attributed to rising global healthcare spending, greater awareness of autoimmune disorders, an increase in combination therapies, higher investments in biotechnology, and a continued rise in autoimmune disease prevalence. Key trends in the forecast period include advancements in technology, the rise of personalized medicine, the expansion of digital health solutions, progress in genetic therapies, and the integration of artificial intelligence.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the hyqvia market. Autoimmune diseases occur when the immune system mistakenly attacks the body’s healthy cells, tissues, or organs, causing inflammation and dysfunction. The rise in autoimmune diseases can be attributed to factors such as genetic predisposition, environmental triggers, dietary changes, increased pollutant exposure, and improved diagnostic methods. Hyqvia is used to treat autoimmune diseases by providing immunoglobulin therapy, which helps regulate the immune system and reduce abnormal immune responses targeting the body’s own tissues. For example, in August 2022, a systematic review of 464 studies published by the National Library of Medicine found 928 cases of autoimmune conditions linked to COVID-19 vaccination. Of these, 81.5% (756 cases) were new-onset autoimmune diseases, with symptoms typically appearing eight days after vaccination. Most affected individuals were women (53.6%) with a median age of 48 years. As a result, the growing prevalence of autoimmune diseases is contributing to the growth of the hyqvia market.

Rising healthcare investment is expected to accelerate the growth of the hyqvia market. Healthcare investment involves allocating financial resources to healthcare businesses, technologies, research, and infrastructure to improve patient outcomes, foster innovation, and support industry growth. Increased healthcare investment is driven by factors such as rising demand for advanced medical treatments, technological innovations, an aging population, and efforts to improve global healthcare access and outcomes. This investment supports the continued development, regulatory approvals, and broader access to Hyqvia, ultimately encouraging its adoption for treating immunodeficiency and CIDP. For example, in December 2023, the U.S. Centers for Medicare & Medicaid Services reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, surpassing the 3.2% growth seen in 2021. Spending on hospital care services rose by 2.2% to $1.4 trillion, and spending on clinical and physician services increased by 2.7% to $884.9 billion. As a result, the growing healthcare investment is propelling the growth of the hyqvia market.

A key trend in the hyqvia market is the development of innovative treatments, such as immune globulin infusion, for conditions such as chronic inflammatory demyelinating polyneuropathy (CIDP) and primary immunodeficiency (PI). Immune globulin infusion involves the administration of antibody-rich plasma proteins to treat immune deficiencies and autoimmune disorders. For instance, in January 2024, Takeda Pharmaceutical Company Ltd. announced that the U.S. Food and Drug Administration (FDA) approved its product, HYQVIA® (immune globulin infusion 10% [human] with recombinant human hyaluronidase), for use as a maintenance therapy for adults with CIDP. This FDA approval allows HYQVIA to be used to prevent relapses of neuromuscular disability and impairment caused by CIDP, a rare neuromuscular disorder affecting approximately five to seven individuals per 100,000 in the U.S.

The key company operating in the hyqvia market is Takeda Pharmaceutical Company Limited.

North America was the largest region in the hyqvia market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in hyqvia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hyqvia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hyqvia is a combination treatment for primary immunodeficiency (PI) in both adults and children. It consists of human immune globulin (IgG) to provide essential antibodies and recombinant human hyaluronidase (rHuPH20) to enhance subcutaneous absorption. Administered every three to four weeks, it allows for larger, less frequent infusions at a single site, offering greater convenience for patients compared to traditional therapies. Hyqvia helps reduce the risk of infections in individuals with low IgG levels due to PI. Common side effects include injection site reactions, headache, and flu-like symptoms.

The primary types of hyqvia patient demographics include pediatric and adult patients. Pediatric patients, under the age of 18, require specialized care to support their growth and development. Hyqvia is distributed through various channels, such as hospitals, specialty pharmacies, home healthcare providers, and retail pharmacies. It is primarily used for conditions such as primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and other related indications.

The hyqvia market research report is one of a series of new reports that provides hyqvia market statistics, including hyqvia industry global market size, regional shares, competitors with a hyqvia market share, detailed hyqvia market segments, market trends and opportunities, and any further data you may need to thrive in the hyqvia industry. This hyqvia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hyqvia market consists of sales of hematology medications, gastrointestinal medications, vaccines, and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.